The effect of brolucizumab on age-related macular degeneratio
Not Applicable
Recruiting
- Conditions
- Age-related macular degeneration
- Registration Number
- JPRN-UMIN000044356
- Lead Sponsor
- Department of Ophthalmology, Juntendo University Faculty of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 50
Inclusion Criteria
Not provided
Exclusion Criteria
Those who are judged by the principal investigator to be inappropriate as research subjects. Those who are judged to have difficulty in going to the hospital on a regular basis. Those who have an intra-ocular inflammation.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method This observational study is planned for 2 years after administration of brolucizumab. An interim evaluation will be made one year after the administration. The main outcome are visual acuity and the retinal status.
- Secondary Outcome Measures
Name Time Method The required number of brolucizumab administration during the observation period. Background factors (age, gender, classification of AMD, past history, and lifestyle) effect on thetherapeutic effect of brolucizumab.